KIT mutations confer a distinct gene expression signature in core binding factor leukaemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Core binding factor (CBF) leukaemias are acute myeloid leukaemia (AML) subtypes with generally favorable prognosis.
• Despite favorable classification, 40-50% of CBF AML patients experience relapse, necessitating risk-adapted therapies.
• Secondary genetic aberrations, particularly KIT gene mutations, are critical in CBF AML pathogenesis and potential therapeutic targets.

Purpose of the Study:

• To investigate the biological underpinnings of KIT-mutated CBF leukaemias.
• To analyze gene expression profiles in CBF AML to identify novel insights into KIT-mutated pathogenesis.
• To explore potential therapeutic implications of KIT mutations and associated signatures.

Main Methods:

• Analysis of gene expression profiles from 83 CBF AML cases.
• Stratification of cases based on KIT mutation status.
• Identification of gene expression signatures associated with KIT mutations.

Main Results:

• KIT-mutated CBF AML cases showed deregulation of genes within the NFkB signaling complex, indicating potential apoptosis control impairment.
• A distinct subgroup of KIT wildtype cases exhibited a KIT mutation signature, suggesting underlying aberrations.
• The findings suggest potential responsiveness to receptor tyrosine kinase inhibitors (TKI) in specific CBF AML subgroups.

Conclusions:

• KIT mutations in CBF AML are associated with specific molecular pathways, notably NFkB signaling.
• A KIT mutation signature in wildtype CBF AML warrants further investigation for potential TKI therapy.
• These molecular signatures highlight biological heterogeneity within CBF leukaemias and may serve as future diagnostic tools.